Overview

A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).
Phase:
Phase 3
Details
Lead Sponsor:
FibroGen